Table 3 Comparison of PedACR and ASAS domains after baseline adjustment
| Â | Â | Week 4 | Week 8 | Week 12 | Treatment P-value* |
|---|---|---|---|---|---|
Physicians' Global | Adalimumab | 2.97 +/- 0,53 | 2.44 +/- 0.53 | 2.67 +/- 0.54 | Â |
5.81# | Placebo | 4.43 +/- 0.57 | 4.43 +/- 0.57 | 4.31 +/- 0.57 | Â |
| Â | Difference (95% confidence Interval) | -1.47 +/- 0.78 | -2.00 +/- 0.78 | -1.64 +/- 0.79 | 0.021 |
Parents' Global | Adalimumab | 3.45 +/- 0.62 | 2.86 +/- 0.62 | 2.85 +/- 0.63 | Â |
5.78 | Placebo | 5.62 +/- 0.66 | 4.75 +/- 0.66 | 5.24 +/- 0.67 | Â |
| Â | Difference (95% confidence Interval) | -2.17 +/- 0.91 | -1.89 +/- 0.91 | -2.39 +/- 0.93 | 0.014 |
No. Active Joints | Adalimumab | 1.72 +/- 0.49 | 1.31 +/- 0.49 | 1.99 +/- 0.5 | Â |
4.31 | Placebo | 2.59 +/- 0.52 | 3.65 +/- 0.52 | 2.83 +/- 0.53 | Â |
| Â | Difference (95% confidence Interval) | -0.87 +/- 0.72 | -2.35 +/- 0.72 | -0.84 +/- 0.73 | 0.032 |
No. LOM Joints | Adalimumab | 1.60 +/- 0.47 | 1.78 +/- 0.47 | 1.84 +/- 0.48 | Â |
3.34 | Placebo | 2.38 +/- 0.50 | 2.65 +/- 0.50 | 2.01 +/- 0.52 | Â |
| Â | Difference (95% confidence Interval) | -0.78 +/- 0.69 | -0.87 +/- 0.69 | -0.17 +/- 0.71 | 0.198 |
CHAQ | Adalimumab | 0.57 +/- 0.12 | 0.42 +/- 0.12 | 0.44 +/- 0.12 | Â |
0.98 | Placebo | 0.80 +/- 0.12 | 0.75 +/- 0,12 | 0.74 +/- 0.13 | Â |
| Â | Difference (95% confidence Interval) | -0.22 +/- 0.17 | -0.34 +/- 0.17 | -0.30 +/- 0.17 | 0.079 |
CRP | Adalimumab | 0.99 +/- 2.77 | 3.92 +/- 2.77 | 1.98 +/- 2.89 | Â |
10.34 | Placebo | 5.91 +/- 3.05 | 8.69 +/- 3.05 | 9.72 +/- 3.05 | Â |
| Â | Difference (95% confidence Interval) | -4.92 +/- 4.14 | -4.76 +/- 4.14 | -7.74 +/- 4.23 | 0.103 |
Spinal inflammation | Adalimumab | 2.60 +/- 0.56 | 2.64 +/- 0.56 | 2.05 +/- 0.56 | Â |
4.73 | Placebo | 3.56 +/- 0.60 | 3.51 +/- 0.60 | 3.50 +/- 0.60 | Â |
| Â | Difference (95% confidence Interval) | -0.97 +/- 0.83 | -0.87 +/- 0.83 | -1.45 +/- 0.83 | 0.179 |
Pain Score | Adalimumab | 3.60 +/- 0.59 | 3.60 +/- 0.59 | 3.23 +/- 0.60 | Â |
5.84 | Placebo | 4.38 +/- 0.63 | 3.98 +/- 0.63 | 4.33 +/- 0.64 | Â |
| Â | Difference (95% confidence Interval) | -0.78 +/- 0.87 | -0.38 +/- 0.87 | -1.11 +/- 0.88 | 0.360 |
Patients' Global | Adalimumab | 4.50 +/- 0.54 | 3.97 +/- 0.54 | 3.76 +/- 0.55 | Â |
6.38 | Placebo | 5.44 +/- 0.58 | 4.70 +/- 0.58 | 4.82 +/- 0.59 | Â |
| Â | Difference (95% confidence Interval) | -0.94 +/- 0.80 | -0.74 +/- 0.80 | -1.06 +/- 0.81 | 0.210 |
BASFI | Adalimumab | 2.53 +/- 0.47 | 2.38 +/- 0.47 | 2.14 +/- 0.48 | Â |
4.00 | Placebo | 3.36 +/- 0.50 | 3.28 +/- 0.50 | 3.09 +/- 0.51 | Â |
| Â | Difference (95% confidence Interval) | -0.84 +/- 0.69 | -0.90 +/- 0.69 | -0.95 +/- 0.70 | 0.171 |